265 results on '"Gold K"'
Search Results
2. Phosphorus-bearing molecules PO and PN at the edge of the Galaxy
3. Evidence of microscopic effects in fragment mass distribution in heavy ion induced fusion-fission reactions
4. Who tells a mother her baby has died? Communication and staff presence during stillbirth delivery and early infant death
5. Making stillbirths visible: a systematic review of globally reported causes of stillbirth
6. HCN and HCO+ in Planetary Nebulae: The Next Level
7. Supplement to: No appointment necessary? Ethical challenges in treating friends and family.
8. OA03.04 Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
9. P19.10 Evaluation of Local Therapy for Oligoprogressive Disease in Metastatic NSCLC Patients on Immunotherapy
10. Navigating care after a baby dies: a systematic review of parent experiences with health providers
11. HCN and HCO + in Planetary Nebulae: The Next Level.
12. STRESS FACTORS AND PSYCHOSOCIAL PROBLEMS FOR CHILDREN AFTER PEDIATRIC LIVER TRANSPLANTATION: 136
13. LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
14. 975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma
15. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options
16. Quality of life of patients with Fabry disease
17. P2.13-10 Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC
18. Retaining nurses via organizational support and pay during COVID‐19 pandemic: The moderating effect between intrinsic and extrinsic incentives
19. CONTINUITY OF CARE AND THE USE OF BREAST AND CERVICAL CANCER SCREENING SERVICES IN A MULTI-ETHNIC COMMUNITY
20. DNR ORDERS: WHO GETS THEM AND HOW LIKELY ARE THEY TO DIE?
21. ARE DNR ORDERS ASSOCIATED WITH LOWER HOSPITAL COSTS?
22. Calibration of the TOPEX altimeter using a GPS buoy
23. Five Years Of Family Medicine Undergraduate Education In Ghana: A Wake-Up Call!
24. Parents’ and healthcare professionals’ experiences of care after stillbirth in low‐ and middle‐income countries: a systematic review and meta‐summary
25. Codeless GPS Applications to Multi-Path: CGAMP
26. Making stillbirths visible: a systematic review of globally reported causes of stillbirth
27. Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial
28. Parents' and healthcare professionals' experiences of care after stillbirth in low- and middle-income countries: a systematic review and meta-summary.
29. Patient or Clinician: Duration of Use of Intrauterine Devices Based on Who Initiated Discussion of Placement
30. 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
31. Maternal complications associated with stillbirth delivery: A cross-sectional analysis
32. Growth characteristics of the mass-reared tintinnid Tintinnopsis beroidea
33. Microgamete formation and the growth rate of Tintinnopsis beroidea
34. Cultivation of marine ciliates (Tintinnida) and heterotrophic flagellates
35. Das Zentrum für Lehre in Regensburg – Vernetzung medizindidaktischer Expertise zur Verbesserung der medizinischen Ausbildung
36. 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study
37. Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses
38. Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases
39. Alk Inhibitor Ap26113 in Patients with Advanced Malignancies, Including Alk+ Non-Small Cell Lung Cancer (Nsclc): Updated Efficacy and Safety Data
40. 1207PD - Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial
41. Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods
42. Maternal complications associated with stillbirth delivery: A cross-sectional analysis.
43. Impact of Chemotherapy Response and Radiation Dose on Overall Survival in Patients With Inoperable Non-small Cell Lung Cancer Treated With Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy
44. L4.1 Evolution of Battle Trials at Md Anderson Cancer Center
45. Lectures
46. Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC).
47. Biologic risk model development for recurrent and second primary tumors (SPTs) in patients (pts) with early stage non-small cell lung cancer (ES NSCLC).
48. Non-Oral Poster 24
49. Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC)
50. Manual of Seed Handling in Genebanks by N. Kameswara Rao, Jean Hanson, M. Ehsan Dulloo, Kakoli Ghosh, David Nowell & Michael Larinde. xiv+147 pp. Rome, Italy: Bioversity International (2006). ISBN 978-92-9043-740-6
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.